TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $72.55, but opened at $62.93. TransMedics Group shares last traded at $63.16, with a volume of 1,848,804 shares changing hands.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on TMDX. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Baird R W raised TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. Robert W. Baird lowered their target price on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a report on Wednesday, December 11th. Finally, Piper Sandler cut their price target on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $122.70.
Get Our Latest Stock Report on TMDX
TransMedics Group Price Performance
The business has a 50-day moving average price of $73.98 and a 200 day moving average price of $121.13. The stock has a market cap of $2.31 billion, a PE ratio of 73.20 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to analysts' expectations of $115.00 million. During the same quarter in the prior year, the company earned ($0.12) EPS. The company's revenue was up 63.7% on a year-over-year basis. As a group, research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.
Insider Buying and Selling at TransMedics Group
In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company's stock, valued at approximately $8,180,642.53. The trade was a 12.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Tamer I. Khayal sold 1,084 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. This represents a 4.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,459 shares of company stock valued at $1,802,244 in the last 90 days. Corporate insiders own 7.00% of the company's stock.
Institutional Investors Weigh In On TransMedics Group
Large investors have recently modified their holdings of the stock. Driehaus Capital Management LLC increased its stake in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company's stock valued at $223,832,000 after purchasing an additional 202,867 shares in the last quarter. Principal Financial Group Inc. increased its position in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock worth $31,759,000 after buying an additional 146,115 shares in the last quarter. Hood River Capital Management LLC purchased a new stake in shares of TransMedics Group in the second quarter worth $18,854,000. Canada Pension Plan Investment Board purchased a new position in shares of TransMedics Group in the second quarter valued at about $16,086,000. Finally, Public Sector Pension Investment Board purchased a new stake in TransMedics Group during the 3rd quarter valued at approximately $11,079,000. Institutional investors own 99.67% of the company's stock.
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Recommended Stories
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
